Related Experiment Video
Updated: Jan 17, 2026

Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo
Published on: July 8, 2025
Paeoniflorin as a potential therapeutic agent for cerebrovascular diseases: A comprehensive review
Yi-Ran Wang1, Ya-Qing Gao1, Zhen-Ling Liu1
1First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
Abstract:
Cerebrovascular diseases (such as ischemic stroke, cerebral hemorrhage, and vascular dementia) are characterized by high incidence and disability rates, posing significant challenges in clinical treatment. Paeoniflorin, a primary active compound derived from the traditional Chinese herb Paeonia lactiflora, exhibits a multi-targeting nature by acting through multiple molecular pathways in the treatment of cerebrovascular diseases. However, its mechanisms of action and efficacy have not yet been systematically reviewed. Therefore, we aimed to summarize the current research progress on paeoniflorin in the field of cerebrovascular diseases and elucidate its pharmacological actions and therapeutic mechanisms. Extensive studies have shown that paeoniflorin exerts neuroprotective effects by suppressing inflammatory responses, alleviating oxidative stress, improving microcirculation, and promoting neural repair and angiogenesis. Its remarkable clinical efficacy and unique mechanisms of action provide novel strategies for cerebrovascular disease treatment and establish a crucial theoretical foundation for developing new neuroprotective drugs, indicating its broad prospects for clinical application and research value. This review aims to summarize the evidence regarding the efficacy of paeoniflorin in treating cerebrovascular diseases, elucidate its multipath pharmacological activities, provide insights for clinical application and novel drug development, and identify potential challenges for future drug development.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...

